MSN Healthcare Solutions works closely with our pathology partners to develop new MIPS Measures for MSN’s – CMS approved – QCDR.
We were successful in adding the following two measures for 2022:
- QMM21:
Incorporating results of concurrent studies into Final Reports for Bone Marrow Aspirate of patients with Leukemia, Myelodysplastic syndrome, or Chronic Anemia - QMM22:
Multi-gene Next-generation Sequencing Panel Recommended on Fine Needle Aspirations (FNA) of Thyroid Nodule(s) with indeterminate Cytology
MSN Healthcare Solutions is a national provider of pathology billing and revenue cycle services. If your current service contract is up for renewal, why not spend a few minutes with us to discuss how our services may benefit your practice.
CONTACT US ABOUT OUR PATHOLOGY BILLING SERVICES
© MSN Healthcare Solutions. All rights reserved. This document and its contents are proprietary and confidential and may not be copied, reproduced, distributed, modified, or otherwise used without the prior written consent of MSN Healthcare Solutions. This document is provided solely for general educational purposes and may not reflect the most current information or the specific laws, regulations, or requirements applicable to your situation; it does not constitute legal advice or a substitute for applicable laws, regulations, or professional legal counsel. Users are responsible for complying with applicable legal and regulatory requirements and should consult qualified legal counsel as appropriate. Read the full legal disclaimer here.


